A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

December 6, 2023

Study Completion Date

December 6, 2023

Conditions
Prostatic Neoplasms, Castration-Resistant
Interventions
BIOLOGICAL

BMS-986218

Specified dose on specified days

DRUG

Docetaxel

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (31)

20089

Local Institution - 0021, Rozzano

20162

Local Institution - 0037, Milan

21287

The Johns Hopkins Hospital, Baltimore

27710

Duke Cancer Institute, Durham

30060

Local Institution - 0004, Marietta

31100

Local Institution - 0003, Toulouse

41124

Local Institution - 0016, Modena

47014

Local Institution - 0071, Meldola

52242

University Of Iowa Hospitals And Clinics, Iowa City

53226

Medical College of Wisconsin, Milwaukee

75028

Texas Oncology, Flower Mound

77702

Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center, Beaumont

80078

Local Institution - 0029, Pozzuoli

97477

Willamette Valley Cancer Institute, Eugene

85711-2701

Arizona Oncology - Tucson - Wilmot Road Location, Tucson

90027-5969

Kaiser Permanente Los Angeles Medical Center, Los Angeles

80120-4413

Rocky Mountain Cancer Centers - Littleton, Littleton

06510-3206

Yale School Of Medicine, New Haven

19713-2055

Medical Oncology Hematology Consultants - Newark, Newark

30322-1013

The Winship Cancer Institute of Emory University, Atlanta

60637-1426

The University of Chicago Medical Center - Duchossois Center for Advanced Medicine, Chicago

63110-1010

Washington University School of Medicine in St. Louis, St Louis

10032-3729

Local Institution - 0006, New York

45245-1995

Oncology Hematology Care, Inc. - Eastgate, Cincinnati

76022-6920

Texas Oncology, Bedford

76201-4315

Texas Oncology - Denton North, Denton

76104-2150

Texas Oncology - Fort Worth Cancer Center, Fort Worth

77030-4004

The University of Texas - MD Anderson Cancer Center - Genitourinary (GU) Cancer Center, Houston

75071-8106

Texas Oncology - McKinney, McKinney

75702-8363

Texas Oncology- Tyler, Tyler

23666-5963

Local Institution - 0056, Hampton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05169684 - A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter